Catheter related bladder discomfort
Conditions
Interventions
Experimental group:At the end of the operation, the patient underwent ultrasound-guided sacral canal nerve block, which was injected with 0.25% Ropivacaine hydrochloride (75mg/100ml) 20ml liquid
Blank control group:None
Sponsors
Fujian Cancer Hospital
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) =60 years old, male; 2) For patients undergoing VATS surgery under general anesthesia, the catheter should be placed in the perioperative period until one day after surgery; 3) American society of anesthesiologists (ASA) Grade I-III; 4) 18 kg/m2=BMI=30 kg/m2; 5) The subjects have a full understanding of the purpose and significance of this trial, voluntarily participate in this clinical trial, and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1) Emergency or emergency surgery; 2) Patients with abnormal spine or spinal cord should not be subjected to sacral canal anesthesia; 3) Puncture site infection; 4) Abnormal urethral anatomy; 5) Patients with increased intracranial pressure or central nervous system injury; 6) There is a history of catheter placement or self-reported symptoms of frequent, urgent and painful urination before surgery; 7) Cauda equina syndrome existed before surgery; 8) A history of chronic drug use or alcohol abuse; 9) Previous history of urinary system disease or surgery (prostatic hypertrophy, urinary obstruction, etc.); 10) Patients with bladder dysfunction, including bladder outflow tract obstruction, neurogenic bladder dysfunction, and overactive bladder syndrome (urination more than 8 times /24h or 3 times/night); 11) Allergic to the ingredients or components of ropivacaine hydrochloride that may be used in the study; 12) Patients with a history of allergic disease, malignant hyperthermia in the past, and epilepsy in the past; 13) Known significant liver disease (Child-Pugh score B or C or presence of ascites); 14) Renal failure (serum creatinine level =1.5 mg/dL); 15) Obvious heart disease (ejection fraction < 50%); 16) Significant chronic obstructive pulmonary disease (forced expiratory volume in 1 second or carbon monoxide dispersion < 50% of the expected value); 17) Subjects with a history of mental illness and cognitive dysfunction; 18) Patients with blood system diseases, coagulation dysfunction or other diseases taking oral warfarin, new anticoagulants such as rivaroxaban, dabigatran; 19) Other circumstances in which the investigator determines that the subject is not suitable for participation in the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of moderate to severe CRBD in PACU; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of moderate-to-severe CRBD 24 hours after surgery;Ramsay score at each time point after operation;Quality of Recovery 15-item Scale (QoR-15) score; | — |
Countries
China
Contacts
Public ContactZhang Xuru
Fujian Cancer Hospital
Outcome results
None listed